Cagrise­ma

Cagrise­ma is an experimental multi-agonist peptide being studied for advanced weight management and metabolic health.
It combines the mechanisms of cagrilintide (an amylin analog that promotes satiety and reduces food intake) with
semaglutide (a GLP-1 receptor agonist that improves glycemic control and suppresses appetite). Together, this dual mechanism targets multiple pathways of energy balance, appetite regulation, and metabolic control. Cagrise­ma remains in clinical development and is not FDA-approved for therapeutic use.

How It Is Used in Research Settings

• Studied for obesity and weight management through dual appetite suppression mechanisms.
• Investigated in type 2 diabetes research for improved glycemic control and insulin sensitivity.
• Explored for cardiovascular and metabolic health improvements beyond weight loss alone.
• Examined in liver health research for potential benefits in NAFLD and NASH models.

Proposed Uses (Research Areas)

• Obesity and advanced weight management research.
• Type 2 diabetes and insulin resistance studies.
• Cardiovascular and lipid metabolism research.
• Liver health studies (NAFLD/NASH).

How It Is Dosed in Research Settings

• Injectable (Subcutaneous): Clinical research trials have studied weekly dosing, with semaglutide components in the 1–2.4 mg range and cagrilintide components in the 1.2–4.5 mg range.
• Titration: Doses are escalated gradually over weeks to improve tolerance and minimize gastrointestinal side effects.
• Cycle length: Studies typically run 24–72 weeks to measure sustained weight loss and metabolic outcomes.
• Handling: Supplied in pre-formulated pens for clinical research; requires refrigeration and protection from light.

Important Considerations

• Regulatory status: Cagrise­ma is not FDA-approved; it remains under clinical investigation.
• Evidence base: Early phase trials suggest additive or synergistic weight loss compared to semaglutide alone, but large-scale outcomes are pending.
• Safety: Reported side effects include nausea, vomiting, constipation, and gastrointestinal discomfort. Long-term safety is still under evaluation.

Disclaimer

This material is provided for educational purposes only and summarizes published research on Cagrise­ma.
It is not medical advice. Cagrise­ma is experimental, not FDA-approved, and should not be viewed as a therapy for medical use.

This peptide is for research use only.